T
Thomas Force
Researcher at Temple University
Publications - 143
Citations - 20770
Thomas Force is an academic researcher from Temple University. The author has contributed to research in topics: Kinase & Signal transduction. The author has an hindex of 66, co-authored 141 publications receiving 19102 citations. Previous affiliations of Thomas Force include Tufts Medical Center & Thomas Jefferson University.
Papers
More filters
Journal ArticleDOI
Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Juan Carlos Plana,Maurizio Galderisi,Ana Barac,Michael S. Ewer,Bonnie Ky,Marielle Scherrer-Crosbie,Javier Ganame,Igal A. Sebag,Deborah A. Agler,Luigi P. Badano,Jose Banchs,Daniela Cardinale,Joseph R. Carver,Manuel D. Cerqueira,Jeanne M. DeCara,Thor Edvardsen,Scott D. Flamm,Thomas Force,Brian P. Griffin,Guy Jerusalem,Jennifer E. Liu,Andreia Magalhaes,Thomas H. Marwick,Liza Y. Sanchez,Rosa Sicari,Hector R. Villarraga,Patrizio Lancellotti +26 more
TL;DR: The noninvasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially car- diotoxic cancer treatment.
Journal ArticleDOI
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkelä,Luanda Grazette,Rinat Yacobi,Cezar Iliescu,Richard D. Patten,Cara Beahm,Brian Walters,Sergei P. Shevtsov,Sergei P. Shevtsov,Stephanie Pesant,Fred J. Clubb,Anthony Rosenzweig,Robert N. Salomon,Richard A. Van Etten,Joseph Alroy,Jean-Bernard Durand,Thomas Force,Thomas Force +17 more
TL;DR: Cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib, where cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death.
Journal ArticleDOI
Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium
Abdul B. Abou-Samra,Harald Jüppner,Thomas Force,Mason W. Freeman,X F Kong,Ernestina Schipani,Pablo Ureña,Julia E. Richards,Joseph V. Bonventre,John T. Potts +9 more
TL;DR: Using expression cloning, a cDNA clone is isolated encoding rat bone PTH/PTHrP receptor from rat osteosarcoma cells that is 78% identical to the opossum kidney receptor and indicates striking conservation of this receptor across distant mammalian species.
Journal ArticleDOI
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu,Tammy F. Chu,Maria Rupnick,Maria Rupnick,Risto Kerkelä,Susan M. Dallabrida,David Zurakowski,Lisa Nguyen,Kathleen C. Woulfe,Elke Pravda,Flavia Cassiola,Jayesh Desai,Suzanne George,David M. Harris,Nesreen S. Ismail,Jey-Hsin Chen,Frederick J. Schoen,Annick D. Van den Abbeele,George D. Demetri,Thomas Force,Ming-Hui Chen,Ming-Hui Chen,Jeffrey A. Morgan +22 more
TL;DR: Left ventricular dysfunction might be due, in part, to direct cardiomyocyte toxicity, exacerbated by hypertension, and patients treated with sunitinib should be closely monitored for hypertension and LVEF reduction, especially those with a history of coronary artery disease or cardiac risk factors.
Journal ArticleDOI
Heart failure: preventing disease and death worldwide.
Piotr Ponikowski,Stefan D. Anker,Khalid F. AlHabib,Martin R. Cowie,Thomas Force,Shengshou Hu,Tiny Jaarsma,Henry Krum,Vishal Rastogi,Luis Eduardo Paim Rohde,Umesh C. Samal,Hiroaki Shimokawa,Bambang Budi Siswanto,Karen Sliwa,Gerasimos Filippatos +14 more
TL;DR: It is time to ease the strain on healthcare systems through clear policy initiatives that prioritize heart failure prevention and champion equity of care for all.